Insider Selling: Steven R. Hagen Unloads 10,797 Shares of Albany Molecular Research Stock (AMRI)
Albany Molecular Research (NASDAQ:AMRI) SVP Steven R. Hagen unloaded 10,797 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $18.99, for a total value of $205,035.03. Following the completion of the transaction, the senior vice president now directly owns 30,933 shares in the company, valued at approximately $587,418. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
A number of research firms have recently commented on AMRI. Analysts at Zacks downgraded shares of Albany Molecular Research from an “outperform” rating to a “neutral” rating in a research note on Tuesday. They now have a $23.70 price target on the stock. Separately, analysts at Morgan Stanley reiterated an “underperform” rating on shares of Albany Molecular Research in a research note on Monday, July 7th. They now have a $15.00 price target on the stock, up previously from $13.00. Finally, analysts at Sterne Agee reiterated an “underperform” rating on shares of Albany Molecular Research in a research note on Monday, July 7th. They now have a $15.00 price target on the stock, up previously from $13.00.
Shares of Albany Molecular Research (NASDAQ:AMRI) traded up 0.42% during mid-day trading on Tuesday, hitting $19.12. The stock had a trading volume of 269,473 shares. Albany Molecular Research has a 52 week low of $9.71 and a 52 week high of $22.30. The stock has a 50-day moving average of $20.12 and a 200-day moving average of $16.85. The company has a market cap of $593.4 million and a price-to-earnings ratio of 38.23.
Albany Molecular Research (NASDAQ:AMRI) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.22 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.20 by $0.02. The company had revenue of $68.20 million for the quarter, compared to the consensus estimate of $65.64 million. On average, analysts predict that Albany Molecular Research will post $0.91 earnings per share for the current fiscal year.
Albany Molecular Research, Inc (NASDAQ:AMRI) is a contract research and manufacturing company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.